Novelia® is now commercialized for the first time for glaucoma in Latin America!August 30, 2016
Our preservative-free multidose eyedropper has been launched in Paraguay with different formulations (branded OFTALMICA):
• Latanoprost + Timolol
• Dorzolamide + Timolol
The use of preservatives can cause allergies or ocular irritation, and some can even cause a toxic response, damaging patients’ eyes[*]. These reactions are even more pronounced when the patient uses combination therapies.
For this reason, patients under chronic treatment, like glaucoma, will appreciate the unpreserved formulations delivered with the multidose Novelia® system.
User-friendly and intuitive, Novelia® contributes to improve patients’ life, allowing the delivery of safe unpreserved eye drops and improving the patients’ adherence to treatments.
Novelia® has also been commercialized in Paraguay for artificial tears, decongestants and anti-allergy applications.
With Novelia®, preserve patient’s eyes, not drugs!
Nemera is a world leader in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: Ophthalmic (preservative-free multidose eyedroppers), Parenteral (autoinjectors, pens, safety devices & implanters), Pulmonary (pMDIs, DPIs), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Dermal /Transdermal (airless & atmospheric dispensers). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.
[*] Report of the International Dry Eye Workshop. Ocul Surf 2007; 5; 65-204.